Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence

Acurx Pharmaceuticals, Inc.

CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.
Acurx opens open-label pilot trial for ibezapolstat in multiply-recurrent CDI (up to 20 patients); first enrollment expected Q4 2026.
Phase 2 data: ibezapolstat achieved 96% clinical cure (25/26) and 100% sustained cure with no recurrence at 1 month (25/25).
Beneficial gut microbiome preservation and bile acid data suggest potential for single-agent treatment and prevention of rCDI.
Company plans to seek FDA approval under LPAD pathway for rCDI treatment and prevention after Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.